title: Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Roider
authors.forename: Josef
authors.initials: J
authors.lastname: Schneider
authors.forename: Michael Joseph
authors.initials: MJ
authors.lastname: Flaig
authors.forename: Thomas
authors.initials: T
authors.lastname: Ruzicka
authors.forename: Christian
authors.initials: C
authors.lastname: Kunte
authors.forename: Carola
authors.initials: C
authors.lastname: Berking
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D003606:Dacarbazine / Q000009:adverse effects*; D005542:Forearm; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D008875:Middle Aged; D012535:Scalp; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D060726:Torso
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine